Who Paid My Doc
Chiayu Chen
Cardiovascular Disease Riverside, CA Medical Doctor
NPI 1972583821 CMS profile 271273
3380 La Sierra Ave Ste 104-170, Ste 104-170, Riverside, CA 92503
General payments
$36,539
Research payments
$1,274
Ownership & investment interest
$0
Research they led as principal investigator
$3,500
Through program year 2024, Chiayu Chen of Riverside, CA is reported in the CMS Open Payments database as having received $36,539 across 530 general payments and $1,274 in research payments paid to them. Separately, studies naming them as principal investigator received $3,500 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 92nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $201 | 5 | |
| 2023 | General | $1,525 | 72 | |
| 2022 | General | $8,223 | 157 | |
| 2021 | General | $20,449 | 103 | |
| 2020 | General | $3,972 | 66 | |
| 2020 | Research | $1,274 | 1 | |
| 2019 | General | $2,169 | 127 |
Beside peers
- Chiayu Chen
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Chiayu Chen were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Chiayu Chen | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,169 | $450 | $127–$1,392 | $163 |
| 2020 | $3,972 | $242 | $77–$751 | $114 |
| 2021 | $20,449 | $335 | $101–$1,037 | $132 |
| 2022 | $8,223 | $395 | $121–$1,211 | $149 |
| 2023 | $1,525 | $443 | $136–$1,283 | $160 |
| 2024 | $201 | $450 | $136–$1,323 | $164 |
| 2025 | $0 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
456
Drug cost
$95,806
Branded share of claims
17.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 19 | $26,758 | |
| Entresto Sacubitril/Valsartan | Brand | 21 | $22,997 | |
| Repatha Sureclick Evolocumab | Brand | 13 | $17,471 | |
| Farxiga Dapagliflozin Propanediol | Brand | 14 | $15,135 | |
| Praluent Pen Alirocumab | Brand | 11 | $6,231 | |
| Ezetimibe | Generic | 91 | $2,538 | |
| Rosuvastatin Calcium | Generic | 55 | $1,237 | |
| Valsartan | Generic | 29 | $789 | |
| Metoprolol Succinate | Generic | 40 | $669 | |
| Atorvastatin Calcium | Generic | 55 | $600 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
2 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| AMVUTTRA |
|
$125 | — | — |
| LEQVIO |
|
$20 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
531 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in California
Ted Love
Cardiovascular Disease · Hillsborough, CA
Paul Kurth
Cardiovascular Disease · Santa Barbara, CA
Jason Rogers
Cardiovascular Disease · Sacramento, CA
Matthew Budoff
Cardiovascular Disease · Torrance, CA
Eric Topol
Cardiovascular Disease · La Jolla, CA
Cathleen Bairey-Merz
Cardiovascular Disease · Los Angeles, CA
Related records
Cardiovascular Disease in California
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.